IPI 549

Drug Profile

IPI 549

Alternative Names: IPI-549

Latest Information Update: 26 Apr 2017

Price : $50

At a glance

  • Originator Intellikine
  • Developer Infinity Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Phosphatidylinositol 3 kinase gamma inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 01 Apr 2017 Interim adverse events and pharmacokinetics data from a phase I/Ia trial presented at the American Association for Cancer Research Annual Meeting 2017 (AACR-2017)
  • 31 Mar 2017 Infinity Pharmaceuticals has patent protection for IPI 549 in USA
  • 31 Mar 2017 Infinity Pharmaceuticals has patents pending for compositions of matter, pharmaceutical compositions, methods of use and synthetic methods for PI3K-gamma programme in World
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top